POMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price Requirement
Nasdaq cancelled the scheduled delisting hearing, and the Class A ordinary shares will continue trading on Nasdaq.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pomdoctor (Nasdaq: POM) regained compliance with Nasdaq’s minimum bid price requirement, as confirmed in a letter received on November 5, 2026.
The requirement under Nasdaq Listing Rule 5450(a)(1) is $1.00 per share. The Nasdaq Hearings Panel hearing scheduled for November 12, 2026 has been cancelled. Pomdoctor received a staff delisting determination letter on October 6, 2026 after its securities’ closing bid price had been below $1.00 for 30 consecutive business days. Its Class A ordinary shares will continue to be listed and traded on Nasdaq under POM.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointCompliance regained with Nasdaq’s $1.00 minimum bid price requirement, confirmed November 5, 2026.
- Minor pointNovember 12, 2026 hearing cancelled following Nasdaq’s confirmation of compliance.
Negative
- None.
Details
Market move: POM +20.44% vs previous close. Nasdaq bid-price compliance
On Nov 6, the day this news came out, the latest delayed price for POM is 20.44% above the previous close. Argus tracked a trough of -10.2% from its starting point during tracking. Our momentum scanner has recorded 56 alerts for this stock so far that day. The latest delayed price is $2.18. Relative volume is very high at 3.8x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Minimum bid price
- $1.00 per share
- Nasdaq Listing Rule 5450(a)(1)
- Prior bid-price deficiency
- 30 consecutive business days
- Closing bid was below $1.00 per share
Historical Context
-
Nasdaq determined bids stayed below $1.00 for 30 consecutive business days.
-
Nasdaq cited failures to meet $50 million and $15 million market-value requirements.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
As a result, the hearing before the Nasdaq Hearings Panel originally scheduled for November 12, 2026 has been cancelled.
As previously disclosed, on October 6, 2026, the Company received a staff delisting determination letter from Nasdaq indicating that the closing bid price of the Company's securities had been below
With Nasdaq's confirmation of compliance, the Company's Class A ordinary shares will continue to be listed and traded on Nasdaq under the ticker symbol "POM."
About POMDOCTOR LIMITED
POMDOCTOR LIMITED (NASDAQ: POM) is a digital healthcare company focused on advancing AI-enabled healthcare solutions and expanding predictive healthcare capabilities. The Company leverages physician resources, wearable technologies, artificial intelligence, healthcare payment networks and real-world healthcare data to support more personalized, continuous and data-driven healthcare services. Building upon its established healthcare platform and physician network, POM is pursuing the development of a predictive healthcare data and services infrastructure designed to improve healthcare outcomes and create long-term value for patients, healthcare providers and other ecosystem participants. For more information, please visit the Company's website: http://ir.7shiliu.com.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC.
For more information, please contact:
POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-regains-compliance-with-nasdaq-bid-price-requirement-302932252.html
SOURCE POMDOCTOR LIMITED
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.